reports
Flow Beverage Corp: 1 director
A director at Flow Beverage Corp sold 160,296 shares at 0.220CAD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
StepStone Group to Announce Fourth Quarter and Fiscal 2024 Results on ...
StepStone Group to Announce Fourth Quarter and Fiscal 2024 Results on May 23, 2024 NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- StepStone Group Inc. (Nasdaq: STEP) today announced that the Company will release its results for the fourth quarter and fiscal year ended March 31, 2024, after the market closes on Thursday, May 23, 2024. Webcast and Earnings Conference Call Management will host a webcast and conference call on Thursday, May 23, 2024, at 5:00 pm ET to discuss the Company’s results for the fourth quarter and fiscal year ended March 31, 2024. The webcast will be made available...
Kraig Biocraft Laboratories Spring Spider Silk Production Trials Excee...
Kraig Biocraft Laboratories Spring Spider Silk Production Trials Exceed Expectations Company Implementing Next Phase of Its Recombinant Spider Silk Business Plan ANN ARBOR, Mich., May 09, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that the spring production trials of the Company's new BAM-1 hybrid parental strains have concluded, exceeding all expectations for scale, performance and robustness. Kraig Labs reports that the spring production trials were an unabashed success. These trials proved that the Compan...
EQS-News: Volta Medical wurde in die neueste Richtlinie der führenden ...
EQS-News: Volta Medical SAS / Schlagwort(e): Sonstiges Volta Medical wurde in die neueste Richtlinie der führenden internationalen Gesellschaften für kardiale Elektrophysiologie zur Ablation von Vorhofflimmern aufgenommen 09.05.2024 / 14:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Volta Medical wurde in die neueste Richtlinie der führenden internationalen Gesellschaften für kardiale Elektrophysiologie zur Ablation von Vorhofflimmern aufgenommen Die im EP Europace Journal veröffentlichte Richtlinie würdigt die KI-basierte Begle...
Genel Energy PLC: Results of AGM
Genel Energy PLC (GENL) Genel Energy PLC: Results of AGM 09-May-2024 / 13:00 GMT/BST 9 May 2024 Genel Energy plc Results of Annual General Meeting 9 May 2024 The Annual General Meeting of Genel Energy plc was held today, Thursday, 9 May 2024 and the results of the votes by shareholders are set out below. The number of ordinary shares of £0.10p each in the Company in issue at the date of the meeting was 279,402,863 and each share attracted one vote. The results were as follows: Resolutions For % Against % ...
Holding(s) in Company
easyJet plc (EZJ) Holding(s) in Company 09-May-2024 / 13:00 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B7KR2P84 Issuer Name EASYJET PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Bank of America Corporation City of registered office (if applicable) Country of registered office (if applicable) US 4. Details of the shareholder Full name of shareholder(...
EQS-News: Volta Medical Featured in Latest Consensus Statement from Le...
EQS-News: Volta Medical SAS / Key word(s): Miscellaneous Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation 09.05.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation Published in the EP Europace Journal, the consensus statement highlights Volta’s AI Companion and the TAILORED-AF clinical tr...
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Mi...
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by end of third and fourth quarter of 2024, respectively Reported positive proof-of-concept for lonigutamab in thyroid eye disease patients and positive top-line Phase 2b/3 data for izokibep in psoriatic arthritis Cash, cash equivalents, and short-term marketable securities at March 31, 2024 of $678.5 million Company...
Sportradar to Participate in the J.P. Morgan Global Technology, Media ...
Sportradar to Participate in the J.P. Morgan Global Technology, Media and Communications Conference on May 21 ST. GALLEN, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company, today announced that Carsten Koerl, Chief Executive Officer, will participate in the J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference at the Westin Boston Seaport District Hotel on Tuesday, May 21, 2024. Mr. Koerl will participate in a fireside chat at 8:10 a.m. EST that morning and that will be webcast...
Bonjour Holdings: 1 director
A director at Bonjour Holdings sold 50,000,000 shares at 0.060HKD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
SPAR Group, Inc. Announces Timing of First Quarter Results Conference ...
SPAR Group, Inc. Announces Timing of First Quarter Results Conference Call AUBURN HILLS, Mich., May 09, 2024 (GLOBE NEWSWIRE) -- SPAR Group, Inc. (NASDAQ: SGRP) (“SPAR”, “SPAR Group” or the “Company”), a leading global provider of merchandising and marketing services, today announces that it will release its 2024 fiscal first quarter results on Wednesday, May 15, 2024, before the market opens. In conjunction with the release, a conference call will be hosted by Mike Matacunas, Chief Executive Officer; and Antonio Calisto Pato, Chief Financial Officer, and will include a Q&A session follow...
WisdomTree Announces Launch of India Equity Hedged Fund (INDH)
NEW YORK--(BUSINESS WIRE)-- WisdomTree, Inc. (NYSE: WT), a global financial innovator, today announces the launch of the WisdomTree India Hedged Equity Fund (INDH) on the NASDAQ. INDH seeks to track the price and yield performance, before fees and expenses, of the WisdomTree India Hedged Equity Index. INDH has an expense ratio of 0.63%. The Index is designed to provide exposure to companies incorporated, listed, and traded in India, while at the same time “hedging” or neutralizing exposure to fluctuations in the value of the Indian rupee relative to the U.S. dollar. “While India’s strong e...
Vera Therapeutics Provides Business Update and Reports First Quarter 2...
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2 trial expected in Q4 2024Pivotal Phase 3 ORIGIN 3 trial estimated to complete enrollment for primary endpoint in Q3 2024; topline data expected in 1H 2025Completed $287.5 million financing, further strengthening the Company’s balance sheet BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Vera Thera...
ORYZON to Provide Corporate Progress Updates at Several Events in May
ORYZON to Provide Corporate Progress Updates at Several Events in May Bio-Equity Europe 2024Asebio Investor Day 2024RSC Hot Topics: Covalent Drug DiscoveryForo Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in May. Oryzon will attend Bio-Equity Europe 2024, wh...
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and C...
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking oral presentation at 2024 SGO Annual Meeting on Women’s Cancer Cash, cash equivalents, and marketable securities of $213.1 million as of March 31, 2024, providing expected cash runway to end of 2026 PRINCETON...
NICE Named the Conversational Intelligence Market Leader in 2024 Opus ...
HOBOKEN, N.J.--(BUSINESS WIRE)-- (Nasdaq: NICE) today announced that Opus Research has named NICE a market leader in Conversational Intelligence (CI) in its 2024 Opus Research Conversational Intelligence Intelliview Report out of 18 vendors evaluated. NICE’s industry leading Enlighten Actions, Enlighten Copilot, Enlighten XO and Enlighten Autopilot were assessed as a part of this research. Opus Research gave NICE the highest possible ratings in three main criteria – Technology and Differentiation, Breadth of Business Impact, and Track Record, Partnerships and Customer Base. Opus Research cl...
Intercept Announces New PBC Data Analyses to be Presented at Digestive...
Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024. The conference will be held from May 18-21 in Washington, D.C. “We are pleased to participate i...
red violet to Present at the B. Riley 24th Annual Institutional Invest...
red violet to Present at the B. Riley 24th Annual Institutional Investor Conference BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced that it will present at the B. Riley 24th Annual Institutional Investor Conference, which is being held May 22-23, 2024 at the Beverly Hilton Hotel in Beverly Hills, California. Derek Dubner, Chief Executive Officer, and Dan MacLachlan, Chief Financial Officer, are scheduled to participate in an analyst-led discussion on Wednesday, May 22, 2024, at 9:0...
Annexon Biosciences to Present at the Bank of America Health Care Conf...
Annexon Biosciences to Present at the Bank of America Health Care Conference BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Bank of America Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT. A live webcast of the event can be accessed under th...
CareCloud Retains Citizens JMP as its Exclusive Capital Structure Advi...
CareCloud Retains Citizens JMP as its Exclusive Capital Structure Advisor SOMERSET, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- (the “Company” or “CareCloud”) (Nasdaq: CCLD, CCLDP and CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced that it has retained Citizens JMP as its exclusive capital structure advisor. The retention of Citizens JMP by the Company was prompted by its recent receipt of an unsolicited indication of interest from a third-party to acquire the Company. The indication of interest proposed a meaningful pr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.